News

12 MAY 2021

Biophytis Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim AnalysisRead the press release

February 17, 2021

Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) following Regulatory Authorities approvals in France and Belgium. Read the Press Release

December 11, 2020

First Patient Enrolled in France in COVA, an International Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of COVID-19 Related Respiratory Failure. Read the Press Release

December 1st, 2020

Biophytis is participating to:
– The Geneva European Midcap digital event, December 1rst & 2 2020
– The “Anticovid” Biotech sector conference organized by the SFAF on Wednesday, December 9
– The 13th International SCWD virtual conference, December 11-13 2020

OCTOBER 26, 2020

Biophytis Enrolls First Patient in Brazil in COVA, a Multinational Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. Read the Press Release

October 16, 2020

Biophitys will participate in the following events:

  • Mid-Cap Event :October 19 & 20th
  • Galien Week of Innovation: Oct 26-30

October 13, 2020

First US Patient Enrolled in COVA, a Multinational Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of COVID-19 Related Respiratory Failure. Read the Press Release

SEPT 8, 2020

Biophytis recently attended the Digital ChinaBio conference taking place August 25-27, and will also attend the following conferences:

  • The HC Wainwright 22nd Annual Global Investment Conference – September 14-16, 2020 (Virtual Conference)
  • The HTID (Health Tech Innovation Days): October 5th & 6th, Paris
  • Bio Europe Fall : October 26-29th (Virtual Conference)

SEPT 1st, 2020

Biophytis Enrolls First Patient in COVA, a Multinational Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. Read the Press Release

August 28, 2020

Biophytis provides an update on SARA-INT, a Phase 2b clinical trial evaluating the efficacy of Sarconeos (BIO101) in the treatment of sarcopenia. Read the Press Release

AUGUST 4, 2020

Biophytis Receives Approval from Brazilian Health Regulatory Agency to Start COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID19 Related Respiratory Failure.  Read the Press Release

JULY 27, 2020

Biophytis Receives Approval from the French Health Authority (ANSM) to Initiate COVA, a Clinical Trial with Sarconeos (BIO101) for the Treatment of COVID-19 Related Respiratory Failure. Read the Press Release

JULY 1st, 2020

Biophytis Receives FDA IND Clearance for COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. Read the Press Release

June 11, 2020

Biophytis Receives MHRA Approval to Initiate the COVA Clinical Trial in the UK with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. Read the Press Release

MAY 20, 2020

Biophytis Receives Approval from the Belgian Regulatory Agency (FAMHP) to Initiate COVA, a Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID19 Related Respiratory Failure. Read the Press Release

APRIL 21, 2020

Correction – Biophytis launches a Public Offering of Share Subscription Warrants (BSA) with an Irreducible Priority Subscription Period for Existing Shareholders.  Read the Press Release

April 7, 2020

Biophytis Announces Launch of a Public Offering of Share Subscription Warrants (BSA) with an Irreducible Priority Subscription Period for Existing Shareholders. Read the Press Release

March 30, 2020

Biophytis Receives Approval from the Belgian Regulatory Agency to Proceed with the MYODA Program for Clinical Development of Sarconeos (BIO101) in Patients with DMD. Read the Press Release

March 3, 2020

Biophytis to Present the Preliminary Results of SARA-OBS and its Impact on SARA-INT, the Phase 2b clinical study, at the 10th International Conference on Frailty and Sarcopenia Research (ICFSR 2020) in Toulouse, France. Read the Press Release

December 16, 2019

Biophytis Receives FDA Approval to Proceed with the MYODA Program for Clinical Development of Sarconeos (BIO101) in Patients with Duchenne Muscular Dystrophy (DMD). Read the Press Release

December 9, 2019

Biophytis Presents Preliminary Analysis of SARA-OBS study at the 12th Annual Congress of The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) in Berlin, Germany. Read the Press Release

16 april 2019

Biophytis announces the release of the 2018 Annual Financial Report and the departure of Jean-Gérard Galvez from the Board of Directors. Read the Press Release

07 december 2018

Biophytis Announces One Oral Presentation and Two Poster Presentations at the 11th International Conference on Cachexia, Sarcopenia and Muscle Wasting. Read the Press Release

28 may 2018

Biophytis receives favourable opinion from EMA for the Orphan Drug designation of Sarconeos in Duchenne Muscular Dystrophy (DMD). Read the Press Release

27 april 2018

BIOPHYTIS updates on clinical development of Macuneos and presents its effects on visual function in a preclinical model of AMD at 2018 ARVO Congress. Read the Press Release

01 march 2018

Biophytis updates on SARA clinical study of Sarconeos in sarcopenia and presents four posters at the International Conference on Frailty & Sarcopenia Research (ICFSR) in Miami. Read the Press Release

03 may 2017

BIOPHYTIS confirms that Sarconeos modulates the Renin-Angiotensin System and activates muscular metabolism in the SARA-PK clinical trial. Read the Press Release

21 february 2017

Biophytis relocates to Pierre and Marie Curie University (UPMC) campus and solidifies creation of leading translational platform for age-related disease. Read the Press Release

04 october 2016

Biophytis to attend the European Large & Midcap Event in Paris – 5-6 October, 2016

08 september 2016

Biophytis will be present at BIOPHARM AMERICA 2016 in Boston, from September 13 to 15

25 july 2016

BIOPHYTIS receives Belgian regulatory authorization to start Sarconeos pharmacokinetics study in elderly healthy volunteers (SARA-PK). Read the Press Release

07 january 2016

Biophytis to present at the Biotech Showcase conference run parallel to the JP Morgan Healthcare Conference (San Francisco, January 11-13, 2016). Read the Press Release

09 march 2015

Involvement in the 3ème Congrès francophone [3rd French-speaking conference] on assessing fragility in elderly subjects – “Prévention de la Dépendance – Rencontres Scientifiques sur la Sarcopénie” [The Prevention of Dependency – Scientific Fora on Sarcopenia] – Paris, 12 and 13 March 2015.